Myeloma

These advancements are changing the way many cancers are being treated.

The success of CAR- (chimeric antigen receptor) T cell therapy is causing landmark change in the way that patients with multiple myeloma are being treated, but more research needs to be done to better understand the role that these agents will play.

A new patient-reported outcomes tool is helping to shift the way end-of-life and depression-related conversations are occurring between patients with multiple myeloma and their health care teams.

The Food and Drug Administration (FDA) granted priority review to the combination use of Darzalex (daratumumab), Velcade (bortezomib), melphalan and prednisone for the treatment of newly diagnosed patients with multiple myeloma who are not eligible for autologous stem cell transplant (ACST).

The Food and Drug Administration (FDA) approved a supplemental new drug application that adds overall survival (OS) data from the phase 3 ENDEAVOR trial to the label for Kyprolis (carfilzomib) to treat patients with relapsed or refractory multiple myeloma.

Over the past few years, the Food and Drug Administration (FDA) has approved a variety of triplet combinations for the treatment of patients with multiple myeloma. However, little is known which regimens have the best economic impact, without sacrificing clinical outcomes that is.

The oldest cases of multiple myeloma and breast cancer date back to ancient Egyptian mummies.

Xgeva (denosumab) was granted approval by the Food and Drug Administration (FDA) to prevent skeletal-related events (SREs) in patients with multiple myeloma, according to Amgen, the developer of the drug.

A drug commonly used to treat patients with multiple myeloma may lead to an increased risk of cardiovascular events such as heart attacks, according to recent research conducted at the Abramson Cancer Center of the University of Pennsylvania.

Researchers found a significant trend toward increased hospice use by people who have multiple myeloma between 2010 and 2013, which indicates that they are receiving more effective pain management toward the end of their lives.

Hosted by comedian, actor and star of “Everybody Loves Raymond” Ray Romano, the 11th Annual Comedy Celebration raised $600,000 to support the work of the International Myeloma Foundation (IMF).

Patients with blood cancers typically value time spent at home in their end-of-life care, however, health care systemts do not always prioritize this in their own quality measures.

A team of six bicyclists trekked across country, from California to Connecticut, to fundraise for the Multiple Myeloma Research Foundation.

At the National Comprehensive Cancer Network® (NCCN)’s Patient Advocacy Summit – a meeting designed to share best practices for survivorship planning care among advocacy organizations – Yelak Biru shared his story of survivorship, and how he has been able to integrate multiple myeloma into his life for more than two decades.

A researcher discusses the exciting times surrounding the development of novel agents designed to treat multiple myeloma.

Don’t people with cancer, as consumers of health care, deserve an equally personalized approach to cancer treatment as we have come to expect in other areas of our daily life?

New treatment regimens may be hitting the scene of myeloma treatment.

Alfred L. Garfall lends insight as to what is new for myeloma treatment.

A new drug, GSK2857916, was granted a breakthrough therapy designation by the FDA to treat patients who have relapsed or refractory multiple myeloma, according to GlaxoSmithKline (GSK), the manufacturer of the agent.

Once weekly Kyprolis (carfilzomib) had better efficacy than lower-doses of the drug given twice a week to treat patients with relapsed/refractory multiple myeloma, according to results from the phase 3 ARROW trial.

The way that newly diagnosed patients with multiple myeloma is treated has changed significantly over recent years, especially as new drugs moved into the treatment realm for the disease, says Shaji K. Kumar, M.D.

Several questions still remain regarding the treatment strategies for elderly patients with multiple myeloma, many of whom may have other comorbidities or trouble tolerating therapies.

Patients with relapsed/refractory multiple myeloma should be given individualized treatment approaches guided by the biology of their disease, frailty of the patient and other comorbidities, said Natalie S. Callander, M.D., who presented on the topic at the NCCN 12th Annual Congress: Hematologic Malignancies in San Francisco, California.

Experts in multiple myeloma share the newest information on the goals of therapy in symptomatic disease, testing for minimal residual disease, the role of transplantation, and the use of maintenance therapy.

Acupuncture is a powerful resource that has been around for thousands of years. The traditional Chinese medicine is effective in treating chronic pain and headaches, and is now being used by many patients with cancer as a complementary therapy alongside medicinal treatment.

For people with multiple myeloma, dollars spent on treatment are being stretched farther than they used to be, a recent study shows.

David S. Siegel, M.D., Ph.D., chief of the division of Multiple Myeloma at the John Theurer Cancer Center, attributes some of the progress in myeloma treatment to patients and how they advocate for themselves.

The Food and Drug Administration (FDA) recently released a statement providing data from the two phase 3 trials testing Keytruda (pembrolizumab) in patients with multiple myeloma. The trials were placed on clinical holds by the FDA in July, after concerns arose regarding the drug’s safety in this group of patients.

Selinexor (KPT-330), a small-molecule inhibitor with a novel mechanism of action, is being investigated in patients with multiple myeloma (MM) who have become refractory to the many new options that have been introduced in recent years for patients with the malignancy.

Peter Voorhees, M.D., discusses the advancements in multiple myeloma treatment, as well as where he hopes the field will go in coming years.